New research reveals that people who discontinue blockbuster slimming jabs like Mounjaro or Wegovy tend to recover shed pounds at a significantly accelerated pace than those who end conventional lifestyle regimens.
Research printed in a prominent health publication points out that while overweight people frequently drop a large proportion of their body weight while using the jabs, the mass is regained at an average rate of 0.8 kg per month upon discontinuation.
"Individuals purchasing such medications need to be aware of the danger of rapid weight regain when the treatment is stopped," warns researcher Dr. Susan Jebb.
That rate of recovery implies a reversion to pre-treatment mass within about a year and a half.
Comparing Therapies
The analysis, which examined dozens of studies involving thousands of patients, compared the effects of GLP-1 agonists with conventional dieting.
Researchers point out that people who shed pounds through diet and exercise usually experience a slower weight regain—approximately 0.1 kg a month—post-intervention.
Explaining the Rapid Rebound
Nutrition scientists believe the mode of action of the jabs is key to understanding the heightened weight return.
The injections imitate a natural hormone called glucagon-like peptide-1, which helps regulate appetite.
"Artificially providing the hormone concentrations several times higher than normal could lead to the body to generate a reduced amount of its own natural GLP-1, and may also diminish responsiveness to its actions," noted Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this GLP-1 'fix' means appetite is no longer kept in check, making excessive eating much more probable."
A Lifelong Disease?
Health authorities suggest the injections for people with obesity-related medical conditions, accompanied by recommended diet and exercise modifications.
Many experts say that, due to the high risk of weight regain, the treatment might need to be ongoing.
This perspective is reinforced by pharmaceutical companies, who note that the findings "emphasize the long-term nature of obesity," akin to managing diseases like high blood pressure.
User Accounts
Users who have stopped the jabs describe a intense resurgence of hunger.
"It felt as if something activating and you become starving," described an individual.
The struggle is compounded if individuals have not adopted lasting lifestyle or habit modifications during therapy.
Significant Adoption
Recent estimates show that millions of people in the UK have used weight-loss jabs in the past year, with desire remaining high.
- Adoption is greater among women compared to men.
- The middle-aged demographic shows the highest level of interest.
- Many access the medications through private prescriptions rather than public health services.
In conclusion, clinicians emphasize that while GLP-1 drugs are powerful agents for shedding pounds, they are not a standalone solution and long-term success relies on ongoing behavioural support.
